Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Sep 2021 Results determining the optimal regimen for the treatment, safety, and efficacy of VP-102 in external genital warts (Pooled results from Part B and Part A of the 6-h and 24-h VP-102) published in the American Journal of Clinical Dermatology
19 Jan 2021 According to a Verrica Pharmaceuticals media release, results presented in poster format online for the 2021 Winter Clinical Dermatology Conference
19 Jan 2021 Results published in Verrica Pharmaceuticals Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com